VIA Pharmaceuticals, Inc. (NASDAQ: VIAP) will present "VIA-319, a Liver-directed Thyroid Beta Agonist for Treating Cardiometabolic Disease" in the Abstract Oral Session on Novel Biological Mechanisms of Atherosclerosis at the American Heart Association Scientific Sessions 2009.The company's Senior VP Research & Development, Dr. Rebecca Taub, will host the company's presentation on November 17, 2009 at 9:15 am (ET). The conference will be located at the Orange County Convention Center, Orlando, Florida Room W304cd.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
